Previous 10 | Next 10 |
The following slide deck was published by AxoGen, Inc. in conjunction with their 2019 Q4 earnings Read more ...
AxoGen (NASDAQ: AXGN ): Q4 Non-GAAP EPS of -$0.10 beats by $0.06 ; GAAP EPS of -$0.18. More news on: AxoGen, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
ALACHUA, Fla., Feb. 24, 2020 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today reported financial results and business highlights for the fourth quarter and full year ended December...
ALACHUA, Fla., Feb. 05, 2020 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or discontinuity to peripheral nerves, today announced that Karen Zaderej, chairman, CEO, and president, will present at the Lee...
ALACHUA, Fla., Feb. 03, 2020 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or transection to peripheral nerves, today announced that it will report fourth quarter and full-year 2019 financial results on ...
Axogen (NASDAQ: AXGN ) announces preliminary Q4 and FY 2019 revenue guidance. More news on: AxoGen, Inc., Healthcare stocks news, Read more ...
ALACHUA, Fla., Jan. 13, 2020 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced preliminary unaudited fourth quarter and full-year 2019 revenue. Preliminary Unaudited F...
ALACHUA, Fla., Jan. 08, 2020 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or transection to peripheral nerves, today announced that its RANGER registry enrollment has reached the milestone of 2,000 nerv...
ALACHUA, Fla., Jan. 02, 2020 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or transection to peripheral nerves, today announced its participation at the combined 2020 meetings of the American Associatio...
ALACHUA, Fla., Jan. 02, 2020 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or transection to peripheral nerves, today announced that Karen Zaderej, chairman, CEO, and president, will present at the JP Mo...
News, Short Squeeze, Breakout and More Instantly...
ALACHUA and TAMPA, Fla., July 23, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that it will report second quarter 2024 financial results on Thursday, August 8, 2024, b...
2024-07-01 07:30:05 ET Raymond James analyst issues OUTPERFORM recommendation for AXGN on July 1, 2024 05:51AM ET. AXGN was trading at $7.24 at issue of the analyst recommendation. Historical Analyst Recommendations Latest 10 recommendations
ALACHUA, Fla. and TAMPA, Fla., July 01, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, announced making an inducement grant on July 1, 2024, under NASDAQ listing rule 5635(c)(4) in conn...